Latest US biosimilar market report from Samsung Bioepis

South Korean drugmaker Samsung Bioepis today released its Second Quarter 2024 Biosimilars Market report, which includes the latest average sales price (ASP) information of all biosimilars and reference products available in the US market.

The company has been publishing the report every quarter since April 2023 to provide the latest market share and price trends of all biosimilars available in the USA, after the Centers for Medicare & Medicaid Services (CMS) publishes updated quarterly ASP values for each product. This fifth-edition delves into some implications of the Inflation Reduction Act (IRA) with respect to biosimilars, as well as the biosimilars market share and price trends.

“Over the past year, we have strived to provide the US market with the latest biosimilar insights through our report, and we are grateful for the positive reception from our readers,” said Thomas Newcomer, vice president, head of market access, US, at Samsung Bioepis. “As we move forward, Samsung Bioepis remains committed to delivering high-quality, safe, and effective biosimilars. Our goal is to be part of the solution in reducing patients' out-of-pocket expenses, while offering savings to the US healthcare system as a whole.” he added.